Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04415047 · ClinicalTrials.gov registry record · NA
The JenaValve ALIGN-AR Pivotal Trial
A NA study of Aortic Valve Disease and Aortic Valve Insufficiency, sponsored by JenaValve Technology.
- Active
- Registry status
- NA
- Development phase
- 180
- Enrollment target
- 20
- Study locations
NCT04415047 is a NA study of Aortic Valve Disease and Aortic Valve Insufficiency that is active but no longer recruiting, run by JenaValve Technology. The registered enrollment target is 180 participants, below the 18,605-participant average among 15 other Aortic Valve Disease trials with a reported enrollment target (99% lower). The trial reports 20 study locations across 14 states.
The verdict
NCT04415047, a NA study of Aortic Valve Disease and Aortic Valve Insufficiency, is active but no longer recruiting, sponsored by JenaValve Technology.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 180 participants
- Enrollment target
- 20
- Study locations
Study Summary
To collect information about treatment for symptomatic severe Aortic Regurgitation (AR), which affects the aortic valve in the heart. Aortic regurgitation is a condition where aortic valve in the heart does not close tightly and allows some blood to leak back into the heart chamber. Symptoms of aortic regurgitation may include fatigue and shortness of breath. The preferred treatment for severe aortic regurgitation is aortic valve replacement surgery.
Conditions Studied
Interventions
- DEVICE JenaValve Trilogy Heart Valve System
Study Locations (20)
California
- Cedars Sinai Medical Center - Los Angeles
- Scripps Hospital - San Diego
- California Pacific Medical Center Research Institute - San Francisco
Ohio
- The Christ Hospital - Cincinnati
- Cleveland Clinic Foundation - Cleveland
- Ohio Health Research Institute - Columbus
Georgia
- Piedmont Healthcare - Atlanta
- Emory University Hospital - Atlanta
Michigan
- University of Michigan - Ann Arbor
- Henry Ford Health System - Detroit
Arizona
- TMC HealthCare & PIMA Heart - Tucson
District of Columbia
- MedStar Washington Hospital Center - Washington D.C.
Florida
- Morton Plant/ BayCare Health - Clearwater
Illinois
- Cardiac Surgery Clinical Research Center Inc./ Advocate Aurora Health - Oak Lawn
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 180 participants |
| Start Date | 2020-05-22 |
| Est. Completion | 2028-08 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04415047
The ClinicalTrials.gov registry entry for NCT04415047 describes a study currently listed as active not recruiting, categorized as NA. The registered enrollment target is 180 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 18,605-participant average among 15 other Aortic Valve Disease trials with a reported enrollment target (99% lower). The listed sponsor is JenaValve Technology, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Aortic Valve Disease appearing as the primary indexed condition, and to 1 intervention - of which JenaValve Trilogy Heart Valve System is the first listed.
NCT04415047 reports 20 study locations spanning 14 distinct geographic areas - top geographies include California, Ohio, Georgia.
Frequently Asked Questions
What is clinical trial NCT04415047 about?
NCT04415047 is a clinical study titled "The JenaValve ALIGN-AR Pivotal Trial". To collect information about treatment for symptomatic severe Aortic Regurgitation (AR), which affects the aortic valve in the heart. Aortic regurgitation is a condition where aortic valve in the heart does not close tightly and allows some blood to leak back into the heart chamber. Symptoms of aort...
What is the current status of trial NCT04415047?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 180 participants. The study started on 2020-05-22. Estimated completion is 2028-08.
What conditions does trial NCT04415047 study?
This clinical trial studies the following conditions: Aortic Valve Disease, Aortic Valve Insufficiency, Aortic Regurgitation, Aortic Insufficiency.
What interventions are being tested in trial NCT04415047?
The interventions under investigation include: JenaValve Trilogy Heart Valve System (DEVICE).
Who is sponsoring clinical trial NCT04415047?
This trial is sponsored by JenaValve Technology, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04415047 being conducted?
This trial has 20 study locations across Arizona, California, District of Columbia, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Aortic Valve Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
The JenaValve ALIGN-AR LVAD Registry
RECRUITING · NA
-
Quantification of Debris Captured Using TCEP During VIV TAVR With BVF
RECRUITING · NA
-
CardioHeartConnect: Commercially Available Fitness for Cardiac Rehabilitation
RECRUITING · NA
-
Avalus Ultra Post-Approval Study (PAS)
ACTIVE NOT RECRUITING · NA
-
J-Valve TF Early Feasibility Study
ACTIVE NOT RECRUITING · NA
-
Early Feasibility Study for the Foldax Tria Aortic Heart Valve
ACTIVE NOT RECRUITING · NA
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.